评估COVID-19疫苗诱导的持久抗体应答:阿根廷圣路易斯教育队列研究
该研究在阿根廷圣路易斯教育系统376名志愿者中,于2021年7月至12月接种新冠疫苗后20、40、120和180天采集871份血清,用ELISA检测抗SARS-CoV-2刺突蛋白受体结合域IgG及中和抗体。至少接种一剂后血清阳性率为93.34%;既往感染者抗体浓度高于未感染者;初次接种6个月后,未感染者中混合接种诱导的抗SARS-CoV-2抗体水平高于其他疫苗;接种后120天,未感染者各疫苗间及未感染者与既往感染者间中和应答无差异。结论提示加强针对既往感染者仍有获益,并提示异源初免-加强方案的优势。
要点
- 至少接种一剂新冠疫苗后血清阳性率为93.34%。
- 既往SARS-CoV-2感染者抗体浓度高于未感染接种者。
- 初次接种6个月后,未感染者中混合接种诱导的抗SARS-CoV-2抗体水平高于其他疫苗。
核心结论
- 对教育系统志愿者的长期分析提供真实世界数据,显示加强针对既往感染者仍有获益,并提示异源初免-加强方案的优势。
研究设计与样本
- 研究在阿根廷圣路易斯教育系统376名志愿者中采集871份血清样本,于2021年7月至12月接种新冠疫苗后20、40、120和180天用ELISA检测抗SARS-CoV-2刺突蛋白受体结合域IgG及中和抗体。
- 志愿者接种BBIBP-CorV(国药)、ChAdOx1 nCoV-19(阿斯利康/牛津,AZ)、Gam-COVID-Vac(卫星V,SpV)或混合疫苗(多为SpV和mRNA-1273,Moderna)。
主要发现
- 至少接种一剂COVID-19疫苗后,检测到93.34%的血清阳性率。
- 既往SARS-CoV-2感染者相比未感染接种者显示更高的抗体浓度。
- 初次接种6个月后,未感染志愿者中混合接种诱导的抗SARS-CoV-2抗体水平高于其他疫苗。
- 接种后120天,未感染接种者中任何疫苗间或未感染与既往感染志愿者间未发现中和应答差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although there has developed an increased interest in the vaccines BNT1622b2 (Pfizer/BioNTech), mRNA-1273 (Moderna/NIAID), and ChAdOx1 nCoV-19 (AstraZeneca/University of Oxford), there are still few reports describing the immune response induced by different vaccine platforms in real-world settings of low-income countries. Here, we proposed to analyse the humoral immune response elicited by the primary vaccines used in Argentina from July-December 2021. METHODS: Anti-SARS-CoV-2-Spike-RBD IgG and neutralising antibodies were assayed by ELISA in a total of 871 serum samples obtained from 376 volunteers from an educational staff. The individuals were vaccinated with BBIBP-CorV (Sinopharm), ChAdOx1 nCoV-19 (AstraZeneca/University of Oxford, AZ), Gam-COVID-Vac (Sputnik V, SpV) or combined vaccines (mostly SpV and mRNA-1273, Moderna). The antibody response was analysed several days after the initial vaccination (20, 40, 120 and 180 days). RESULTS: After receiving at least one dose of the COVID-19 vaccine, we detected 93.34% of seroprevalence. Previously SARS-CoV-2 infected showed higher antibody concentrations compared with naïve vaccinees. Six months after the initial vaccination, combined vaccination induced higher anti-SARS-CoV-2 antibody levels than the other vaccines in naïve volunteers. However, we did not find differences in the neutralising responses after any vaccine from naïve vaccines or between the naïve and previously infected volunteers on day 120 after vaccination. CONCLUSIONS: Our long-term analysis of volunteers from the educational system provides data in a real-world context, showing the benefits of a boost dose still in previously infected volunteers, and suggesting the advantages of a heterologous prime-boost schedule.
引用
- Eliçabe RJ, Distel MN, Jofré BL, et al. Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina. Vaccine. 2022. PMID: 36481109. doi:10.1016/j.vaccine.2022.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。